ArticleJournal of Crohn's & colitis2026
Correction to: Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.